Adverse events
| SRS and Ipilimumab (n = 45) | SRS and Nivolumab (n = 35) | |||
|---|---|---|---|---|
| Grade 1 or 2 | Grade 3 | Grade 1 or 2 | Grade 3 | |
| Number of patients with at least an adverse eventa | 31 (68%) | 11 (24%) | 20 (57%) | 6 (17%) |
| Event | ||||
| Diarrhoea | 11 (24%) | 3 (7%) | 5 (14%) | 1 (3%) |
| Nausea or vomiting | 8 (18%) | 1 (2%) | 4 (12%) | 1 (3%) |
| Constipation | 5 (11%) | 0 | 2 (6%) | 0 |
| Increased AST and/or ALT levels | 4 (9%) | 2 (4%) | 4 (12%) | 2 (6%) |
| Fatigue | 12 (27%) | 3 (7%) | 6 (18%) | 2 (6%) |
| Endocrine immune disorders | 3 (7%) | 0 | 2 (6%) | 0 |
| Rash/Pruritus | 10 (22%) | 1 (2%) | 6 (18%) | 1 (3%) |
| Arthralgia | 5 (11%) | 0 | 3 (9%) | 0 |
| Muscle weakness right or left sided | 3 (7%) | 1 (2%) | 2 (6%) | 1 (3%) |
| CNS event | ||||
| Headache | 8 (18%) | 2 (4%) | 4 (12%) | 1 (3%) |
| Hemorrhage | 3 (7%) | 1 (2%) | 2 (6%) | 1 (3%) |
| Seizure | 3 (7%) | 2 (4%) | 2 (6%) | 1 (3%) |
| Diziness | 4 (9%) | 0 | 2 (6%) | 0 |
| Brain necrosis | 13 (29%) | 5 (11%) | 7 (20%) | 3 (9%) |
| Discontinuation of treatment | 5 | 3 | ||
aTreatment-related adverse events of any grade occurring in at least 5% of patiens in either cohorts. Some patients had more than one event. No grade 4 events were reported in both cohorts